King's College London

Research portal

Chemotherapy-related cardiomyopathy

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)19-24
Number of pages6
JournalEuropean Cardiology
Issue number1
Accepted/In press23 Jul 2015

King's Authors


Advances in chemotherapeutic agents have resulted in significantly improved cancer survival rates. Cardiac toxicity, however, has emerged as a leading cause of morbidity, both during and years after treatment. One of the most common manifestations of cardiotoxicity is that of heart failure and left ventricular systolic dysfunction. In this review, current opinions and guidelines in this field are discussed, with particular focus on the most common culprits, the anthracyclines, and the monoclonal antibody, trastuzumab.

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454